CSIR gets nod for Phase III trial of antiviral drug Umifenov
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The CSIR -- Central Drug Research Institute (CDRI) Lucknow, has got the nod for carrying out a clinical trial of antiviral drug Umifenovir for treating coronavirus patients, according to a statement.

The Phase III clinical trials will be carried out at King George’s Medical University (KGMU), Dr. Ram Manohar Lohia Institute of Medical Sciences (RMLIMS), and ERA’s Lucknow Medical College & Hospital, Lucknow, it added.

The drug has a good safety profile and acts by preventing entry of viruses into human cells and also by priming the immune system, it added.

Umifenovir is mainly used for the treatment of influenza and is available in China and Russia, and has recently come into prominence due to its potential use for Covid-19 patients.

To evaluate its efficacy in Indian patients, CSIR-CDRI has taken up the clinical trial.

Prof. Tapas Kundu, Director CSIR-CDRI, said all the raw materials for the drug are indigenously available and if the clinical trial is successful, Umifenovir can be safe, efficacious, and affordable drug against COVID-19. He added that the drug has the potential for prophylactic use.

Source: https://www.hindustantimes.com/india-news/covid-19-csir-institute-to-conduct-clinical-trials-of-antiviral-drug-umifenovir/story-JA6S6qzibAWNLEdYwARPXL.html
Dr. T●●●●z H●●●●●●i and 2 other likes this3 shares
Like
Comment
Share